I nterferon gamma (IFN-␥) is a pleiotropic interferon, and it is known to regulate Ϸ500 genes. 1 It has long been thought to be involved in the pathogenesis of atherosclerosis. The well known properties of IFN-␥ include its ability to induce inflammatory genes (eg, ICAM-1, VCAM-1), cell signaling molecules (CD40, CD80, tissue factor, MHC class II antigen) on endothelial cells, and macrophages. 2 This results in enhancement of the antigen-presenting properties of macrophages and endothelial cells and induces a proinflammatory phenotype of endothelial cells. IFN-␥ also has effects on cholesterol and lipid trafficking. The consensus is that presence of IFN-␥ in atherosclerotic plaques has a deleterious effect, possibly by enhancing plaque instability and plaque rupture. 2 In this issue of Circulation Research, 3 Wang et al have published a report, the third in a series, which provides compelling evidence that IFN-␥ plays a nonredundant role in pathogenesis of alloimmune-induced vascular intimal hyperplasia, a condition that occurs after cardiac allograft transplantation. The results of this study have therapeutic implications for all vascular diseases where smooth muscle hyperplasia occurs, and the mechanisms of its actions are unrelated to the previously described effects of IFN-␥ on endothelial cells or macrophages.
Cardiac transplantation is a successful therapeutic option for patients with end stage heart failure that cannot be treated by conventional surgery or medication. Whereas 1-year survival has been impacted by improvements in immunosuppression, long-term survival remains relatively unchanged; 10-year survival of combined adult and pediatric transplant recipients is currently 50%. 4 A major reason for this is development of cardiac graft vasculopathy (CGV), an occlusive vascular disease of grafted vessels which results in altered blood flow in the arteries and ischemia to the heart. Histologically, there are similarities and differences between CGV and nontransplant atherosclerosis. 5 In CGV affected vessels demonstrate loss of medial cells and an expanded intima consisting of extracellular matrix, infiltrating mononuclear cells, and vascular smooth muscle cells. The presence of proliferating smooth muscle cells is also a feature of in-stent restenosis, and to a lesser extent nontransplant atherosclerosis.
It is paradoxical that although acute rejection is modified by treatment with immunosuppressive drugs in routine use (such as calcineurin inhibitors, and inhibitors of purine synthesis) these drugs have little impact on CGV. In contrast, the recently introduced drug, Everolimus, an mTOR (mammalian target of rapamycin) inhibitor, produces less intimal thickening in the arteries of treated patients. 6 It is not clear whether the effect of mTOR inhibitors are a direct effect on smooth muscle cell proliferation 7 or their antiproliferative effects on lymphocytes. 8 As with all chronic human diseases, it is difficult to produce an adequate model of cardiac graft vasculopathy. In vitro studies using clinical materials are limited by the artificial nature of culture conditions. Experiments in vivo are limited because of the difficulties in extrapolating from animal to human cell-cell interactions. Progress in this area has proceeded using a xenotransplantation model; namely transplantation of human epicardial arteries into C.B-17 severe combined immunodeficient beige mice, followed by repopulation of the mouse with gamma interferon, 9 human leukocytes, 10 or in the most recent study, replication deficient adenovirus encoding the human transgene for IFN-␥. 3 The advantage of using adenovirus (AAV) to transfer human IFN-␥ was that it produced higher circulating levels of IFN-␥ than were previously achieved by daily injection, 9 and levels could be maintained for as long as 14 weeks. Four weeks exposure was sufficient to result in an expanded intima of the human epicardial arteries, consisting of matrix and smooth muscle cells; in contrast mice given adenovirus containing a control gene failed to show intimal expansion. The authors went on to explore the pathways involved in IFN-␥-mediated human vascular SMC proliferation.
Cellular proliferation is associated with activation of the mammalian target of rapamycin, mTOR. mTOR is an evolutionary conserved protein kinase, it was identified and cloned 10 years ago (1994) shortly after its initial discovery in yeast, during a screen for the immusuppressive drug rapamycin. It is now known to be a major effector of cell growth and proliferation via the regulation of protein synthesis. 11 It regulates protein synthesis via recruitment of the ribosomal protein S6 and its kinase ribosomal S6 kinase (S6K1). Phosphorylation of S6 is thought to be a general mechanism to signal and induce cell growth and proliferation. 11 mTOR may also regulate transcription of ribosomal RNA (rRNA; Figure) . The upstream signaling pathway of mTOR is mediated via phosphorylation of phosphatidylinositol 3-kinase (PI3K) at the cell membrane, this leading to phosphorylation of Akt. The PI3K pathway is activated by extracellular signals such as growth factors, hormones, and mitogenic stimuli 11 (Figure) . Wang et al demonstrate the presence of phosphorylated S6K1 in xenografts from mice treated with AAV/IFN-␥, but not controls, suggesting activation of the mTOR pathway by IFN-␥. They showed that SMC proliferation and phosphorylation of S6K1 in the presence of AAV/IFN-␥ was inhibited if animals were treated with 1.5 mg/kg rapamycin/d. In vitro studies of denuded arteries or cultured SMCs confirmed that IFN-␥ caused phosphorylation of mTOR, S6K1, and S6 in a time-dependent and dosedependent way. The fact that these effects were mediated in SMCs or arteries maintained in serum-free medium is important because it shows that IFN-␥ has a direct effect on SMCs and is not mediated via growth factors (such as plateletderived growth factor). Finally, as expected, it was demonstrated that IFN-␥-mediated phosphorylation of mTOR, S6K1, and S6 was inhibited by the PI3K inhibitor LY294002.
It is interesting that early studies (reviewed in 2 ) suggested that IFN-␥ had an inhibitory effect of proliferation of vascular SMC; however, these were short-term in vitro studies using cultured cells, in vivo studies have the advantage of long exposure to circulating cytokines and maintenance of normal vessel architecture. 10 suggesting a nonredundant role for IFN-␥ in alloimmune induced vascular smooth muscle cell proliferation. This hypothesis is supported by experimental studies which demonstrate decreased cardiac allograft vasculopathy when hearts have been allotransplanted into mice lacking the gene for IFN-␥. 12, 13 One of the questions arising from this notion is the cellular source of the IFN-␥ in the affected arteries. Interferon-␥ is made by CD4ϩ T cells, CD8ϩ T cells, activated macrophages, NK cells, B cells, and vascular smooth muscle cells. 2 With the exception of NK cells, all these cell types are present in the intima and adventitia of coronary arteries from patients with cardiac graft vasculopathy. 14 Indeed the infiltrating cells in the vessel wall occupy a discreet area within the expanded intima which is between the acellular and smooth muscle cell rich component, making them well placed to activate SMC by local secretion of IFN-␥. It is interesting to speculate whether activation of IFN-␥ producing T lymphocytes occurs locally within the graft; the presence of alloantigen displayed by dendritic cells and endothelial cells in the graft may be sufficient to cause local activation of graft infiltrating memory CD4ϩ and CD8ϩ T cells, allowing them to further differentiate and produce IFN-␥. 15 Taken together 3, 9, 10 these experiments provide compelling evidence that human IFN-␥ causes smooth muscle cell proliferation in vivo, via activation of the PI3 kinase/mTOR pathway (Figure) . IFN-␥ stimulates transcriptional activity through Stat-1complex 16 ; however, Stat-1-independent mechanisms of IFN-␥ activation also exist. The exact pathways by which IFN-␥ stimulate PI3K are currently not known. There results provide a new mechanistic insight into the role of IFN-␥ in vascular disease and may have therapeutic implications for all vascular disease characterized by smooth muscle cell proliferation. In the cases of flow or mechanically-induced restenosis injury, the question remains whether SMC proliferation is dependent on IFN-␥.
Wang et al have published that inhibition of IFN-␥ with neutralizing antibodies inhibits intimal expansion induced by allogeneic T cells in SCID-Beige mice
Finally, as acknowledged by the authors, 3 IFN-␥ is unlikely to be the only player in the sequence of immune events which cause CGV. In vitro studies have shown that alloantibody also causes phosphorylation of PI3K and of S6 ribosomal protein in vascular smooth muscle cells, 17 although whether this leads to growth factor-independent cell proliferation has not been determined. S6RP was found in cardiac biopsies to be associated with humoral rejection, rather than cellular rejection. 17 In view of the association between alloantibodies and graft vasculopathy, 18 it might be of interest to test for a synergistic effect between alloantibodies and IFN-␥ in SMC proliferation, using this elegant in vivo xenotransplant model.
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Activation of the Akt/mTOR pathway. Diagrammatic representation demonstrating that mTOR activation regulates protein synthesis via phosphorylation of ribosomal protein S6 and activation of initiation factors such as eIF4B. In addition, it exerts transcriptional control of ribosomal RNA (rRNA) by modulating various transcription factors and enzymes (RF, or regulatory factors); these will affect global protein synthesis. Inhibitors of this pathway include PTEN, which inhibits PI3K activation and rapamycin which inhibits mTOR. Modified from Ruggero and Sonenberg 11 with permission from Macmillan Publishers Ltd, Oncogene, 2005.
